Special episode (ESC 2025: AQUATIC, VICTOR) https://t.co/UH2E0rGpE5

We recorded a special episode discussing major trials presented at the ESC 2025 and will discuss more ESC 2025 trials soon w/ @AndrewFoy82 & @drjohnm See our substack link below and find us on Apple Podcast and Spotify “Cardiology Trials” https://t.co/qR9Xjn6Uax

Also see the original reviews on our substack https://t.co/qR9Xjn6mkZ

Two important trials of beta-blockers in patients with heart. The negative results of BEST has to do more with patients characteristics (high risk patients enrolled) and less with bucindolol @CVtrials W/ @AndrewFoy82 & @drjohnm

This is a great discussion of the BEST trial (beta-blockade in systolic heart failure) - by @AndrewFoy82 Not many know this trial which was negative. Andrew discusses why the results differ from other BB trials New trials’ reviews coming soon w/ @AndrewFoy82 and @drjohnm

Great comments by @AndrewFoy82 and @drjohnm on how/when to initiate beta-blockers in systolic heart failure. You can find the full episode on Apple podcast, Spotify and substack https://t.co/MHXruy7K2R https://t.co/cmaB9jxqfc https://t.co/qR9Xjn6Uax

I just recorded an excellent podcast with @AndrewFoy82 @MRuzieh on the below HF trials. Coming Friday on @CVtrials I learn so much from these two. Teaser: there is a bunch of nuance in our GDMT evidence

Guidelines still recommend using beta-blockers after MI. @MRuzieh and @AndrewFoy82 explain that the evidence underpinning this practice is outdated. And newer trials fail to confirm beta-blocker benefit. This is a classic case of evidence requiring an expiration date.

A really eye-opening review of the Dig Trial over at @CVtrials I don't know you all...digoxin should not be demonized. Take a read or listen to @AndrewFoy82 review https://t.co/EJfKIzHDVx

We have reviewed 84 seminal trials @CVtrials w/ @AndrewFoy82 & @drjohnm These trials covered the topics of stable CAD and acute coronary syndromes. We will be reviewing heart failure trials next and you will see many surprises then! Follow our substack

Not everyone with NSTEMI should go to the cath lab, and you should be more and more selective in older patients Listen to our discussion @CVtrials with @AndrewFoy82 and @drjohnm

@GorcsanMd @Mike_P_Pfeiffer @BPetersonCardio @MRuzieh

The increase in MI in ICTUS was driven by procedural-related MI. No significant difference in MI in RITA 3. None of these trials showed reduction in all-cause death

This week @CVtrials, we discussed revascularization for NSTEMI. This is a heterogeneous group of patients and coronary angiogram is not appropriate for all. Early invasive approach reduced MI in TACTICS-TIMI 18 but increased it in ICTUS @AndrewFoy82, @drjohnm

Happy to share our latest work regarding assessment of the right ventricle in intermediate risk PE patients in JAHA ⁦@Mike_P_Pfeiffer⁩ ⁦@BPetersonCardio⁩ ⁦@MRuzieh⁩

Let us know your interpretation of the trials and how your practice changed

Listen to @AndrewFoy82 discussion of why COMPLETE adjudication of myocardial infarctions was problematic.

This week @CVtrials we discussed complete vs culprit only PCI in STEMI patients with multi vessel CAD. @AndrewFoy82 & @drjohnm The PRAMI (small trial) and COMPLETE (large trial) showed benefit of complete revascularization while FULL REVASC (stopped early) showed no benefit

Previous obs studies suggest that left atrial appendage occlusion reduce mortality @MRuzieh et al do a more careful analysis of the same Medicare database and confirm the findings of RCTs that pLAAO does not reduce mortality at one year. Impressive work

TAPAS showed large treatment effect size favoring thrombus aspiration in terms of coronary flow and ST segments resolution. It also showed numerically better outcomes with thrombus aspiration. TASTE, a much larger trial powered for clinical outcomes, was negative.